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 Introduction  1 
1  Introduction 
Life sciences is a term used to define any research that is concerned with living 
objects, either animals or plants. This covers medicine, biology, biotechnology, 
genetics, biochemistry, organic chemistry, and others. There is no strict and clear-
cut definition of the term “life sciences”, which is broadly used in this report to also cov-
er medical equipment and instruments as well as pharmaceuticals. As this report is 
about China and Chinese activities in the life science sector, it is a prerequisite to also 
focus on TCM (Traditional Chinese Medicine). TCM is to be analyzed in this report only 
from its technological perspective, although we are aware that TCM involves more than 
just the herbs, agents, etc. 
This report aims to describe the Chinese scientific and technological activities and their 
international competitiveness in the life sciences sector using quantitative indicators. In 
consequence, this study only focuses on quantifiable activities and outputs. 
2  R&D programs and policies 
The role of the life sciences in national policies is a first indication of their standing in 
the sciences and in the economy in general. As a starting point, policies and programs 
related to TCM, life sciences, and public health are briefly considered in this section. 
The three-year budget of the Chinese government in public health and medicine 
from 2009 to 2011 is 850 billion RMB.1 In addition, the Ministry of Health of China will 
receive $5.88 million from the World Health Organization (WHO) in 2010-2011 to sup-
port 73 public health programs in more than 20 provinces in mainland China. The key 
fields in which programs can be funded include public health emergencies, epidemics, 
food safety, and chronic disease prevention and control, women and children's welfare, 
medical infrastructure in rural areas, and the development of Chinese Traditional Medi-
cine.2
Biotechnology has been identified as one of the frontier technologies in the Na-
tional Medium-  and Long-term Science and Technology Development Plan (2006-
2010).  Frontier technologies are considered to represent a nation's comprehensive 
high-tech innovation capability. Five subfields – target identification technology, plant-
animal species and drug molecular design technology, gene manipulation and protein 
 
                                                 
1  http://www.gov.cn/jrzg/2009-04/06/content_1278711.htm. Retrieved on March 8 2010. 
2  http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohgjhzs/s3578/201003/46177.htm. 
Retrieved on March 8 2010. 2  Indicators 
engineering technology, stem-cell based human tissue engineering technology, and 
new generation of industrial biotechnology – are specifically prioritized. 
In the Eleventh National Five-Year Plan (2006-2010), around 30 national S&T centers 
and laboratories with advanced equipment were to be built in the life sciences and oth-
er key fields (IT, aerospace, marine sciences, nanotechnology, and new materials). 
Additionally, 12 national key S&T infrastructure programs include labs and equipment 
for protein research and agricultural safety research. Moreover, with respect to tech-
nological innovation, important new drugs, epidemic protection and control, as well as 
modern TCM have been emphasized.3
The executive meeting of the State Council recently passed the implementation plan 
of the "Major New Medicine Creation" science and technology program, which is 
part of the National Twelfth Five-Year Plan, and the call for project applications was 
announced through three government websites  –  the Ministry of Health 
(www.moh.gov.cn), the Ministry of Science and Technology (www.most.gov.cn), and 
the China National Center for Biotechnology Development (www.cncbd.org.cn). The 
framework of the program is similar to that in the previous Five-Year Plan, and sup-
ports projects in the following five areas: (1) R&D on innovative medicine; (2) Technol-
ogical upgrade of medicine in major categories; (3) Technology platform building for 
innovative medicines R&D; (4) Incubation foundation building for enterprises' innova-
tive medicine; and (5) Research on key technologies for new medicines R&D. The fi-
nancial support ranges from 3 to 25 million RMB for each project, with a goal of (1) 
promoting indigenous innovation of medicines with minimal side-effects which meet 
international standards and large market demands, and (2) building technology plat-




3  Indicators 
. 
3.1  Research and Development (R&D) Expenditure 
The expenditure on research and development (R&D) is the basis and foundation of 
any success in high-tech markets. The expenditures – effectively this means the remu-
nerations of the researchers – are an indication of the amount of R&D activities, which 
                                                 
3  http://www.gov.cn/ztzl/kjfzgh/content_883887.htm. Retrieved on March 12, 2010. 
4  http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohkjjys/s3578/201005/47320.htm. 
Retrieved on May 26, 2010. Indicators  3 
represent the structured and goal-oriented quest for new technologies and new re-
search findings. So R&D expenditure is an input to the innovation process and thereby 
reflects the activity level or the relevance of certain scientific or technological areas. For 
these reasons it is important to have information about the level of R&D expenditures 
and where they are spent. 
Table 1:  Gross domestic expenditure (in million US$) on R&D by sector of perfor-
mance and field of science in China, 1998-2007 
  1998  2000  2002  2004  2007 
Total  55112  89567  128760  196633  371024 
Natural sciences and engineering   54154  86564  125199  191898  363378 
Natural Sciences  3019  7893       
Engineering  46763  72321       
Medical Sciences  1364  3635       
Agricultural Sciences  3008  2773       
Social sciences and humanities  958  522  1764  2765  5072 
Not elsewhere classified (fields of 
science)   
2481  1797  1970  2575 
As a percentage of the total 
Natural sciences and engineering  98.3%  96.6%  97.2%  97.6%  97.9% 
Natural Sciences  5.5%  8.8%       
Engineering  84.9%  80.7%       
Medical Sciences  2.5%  4.1%       
Agricultural Sciences  5.5%  3.1%       
Social sciences and humanities  1.7%  0.6%  1.4%  1.4%  1.4% 
Not elsewhere classified (fields of 
science) 
  2.8%  1.4%  1.0%  0.7% 
Source: OECD - Main Science and Technology Indicators; Fraunhofer ISI calculations. 
China's expenditure on R&D has increased considerably over the last decade. The 
absolute amount in the year 2007 is more than five times the expenditure of 1998 
(Table 1). Most of this is dedicated to natural sciences and engineering, which account 
for 97-98% of total spending. More than 80% of the expenditure targeted engineer-
ing activities  and  about  another  9% (in 2000) was  dedicated to  the  natural 
sciences. Medical sciences account for less than 5%, but increased considerably be-
tween 1998 and 2000. In 2007, almost 62% of the business expenditures on S&T activ-
ities by large and medium-sized enterprises targeted  electronic and communication 
equipment (Table 2). Another 10% were spent on computer and office equipment R&D 
and almost 12% on aviation. Companies spent 13.2% (more than 11.7 billion Yuan) 4  Indicators 
on medical and pharmaceutical products research and another 6.1% on medical 
treatment instruments and meters. It is remarkable that about 32% of the expendi-
ture of large and medium-sized companies on modernizing technical equipment was 
spent on medical and pharmaceutical products as well as medical treatment instru-
ments and meters. This reflects, on the one hand, the necessity to invest in the labora-
tories and research institutions. On the other hand, this also reflects the demand – or at 
least the intention – to rejuvenate the input into the R&D system and the goal of be-
coming competitive on an international level. 
Table 2:  Inputs of large- and medium-sized enterprises in science and technology 






















































































































































































Total  478284  248228  213822  8868253  5453244  6520284  2109878 
Medical and pharma-
ceutical industry  73408  30778  25377  1169417  658836  739435  473091 
Chemical medicine  45227  19302  15558  726795  418799  470476  315245 
Traditional Chinese 
Medicine (TCM)  18005  7420  6519  273222  156873  176588  112305 
Biological & biochemical 
products manufacturing  5427  2769  2294  93701  55225  51628  15756 
Medical equip. and 
instr. manufacturing  39822  18148  15330  544915  305093  400493  204991 
Medical equipment and 
instruments  6637  3468  2935  105818  73163  87086  41668 
Other equipment and 
instruments  33185  14680  12395  439097  231930  313408  163323 
Note: * FTE = Full time equivalents; S&T means Science and Technology, which is a broader 
term than R&D as it covers additional expenditures. 
Source: China Statistical Yearbook (2008); Fraunhofer ISI calculations. 
Table 3 shows the distribution of NSFC-funded life sciences and TCM projects in the 
period 2001 to 2008. As can be seen, the number of projects has a more or less con-
stant share slightly above 1/3 in the portfolio of the National Science Foundation of 
China. Less than 3% of all NSFC projects concern Traditional Chinese Medicine. The 
rate of acceptance of TCM projects is also quite constant. One project out of 7 or 8 
applications is finally funded by the NSFC. Indicators  5 
Table 3:  The distribution of NSFC-funded life science and TCM projects**, 2001-
2008 
  Life sciences**  TCM  Total NSFC  LS/Total  TCM/Total 
2001  1,667  107  4,931  33.8%  2.2% 
2002  2,406  203  6,676  36.0%  3.0% 
2003  2,619  177  7,097  36.9%  2.5% 
2004  3,314  252  8,619  38.4%  2.9% 
2005  3,539  251  9,831  36.0%  2.6% 
2006  4,107  297  11,246  36.5%  2.6% 
2007  4,944  384  14,169  34.9%  2.7% 
2008  5,889  431  16,414  35.9%  2.6% 
Source: Deng, Xu (2009); Fraunhofer ISI calculations. 
Note: *NSFC-funded projects are classified into general, key, and major projects **Life sciences 
include many sub-fields: microbiology, botany, ecology, forestry, biophysics, biochemistry, mo-
lecular biology, immunology, neurology, cognitive psychology, physiology, integrated biology, 
genetics, bioinformatics, cytobiology, biology of reproduction and evolution, food science, agri-
culture and agronomy, horticulture, plant protection and nutrition zoology, zootechnics, veteri-
nary medicine, and fishery science. 
Table 4:  Applied and accepted NSFC projects in the field of TCM, 2001-2008 




Rate of acceptation 
(projects ) 
2001  169.5  19.0  12.8% 
2002  220.3  26.0  14.0% 
2003  243.1  30.9  16.0% 
2004  12,233.5  44.4  15.7% 
2005  9,589.9  57.6  12.6% 
2006  721.8  71.3  12.2% 
2007  2,243.5  58.8  11.4% 
2008  4,426.2  76.6  13.3% 
Source: Deng, Xu (2009); Fraunhofer ISI calculations. 
3.2  Publications 
The research output of Chinese authors in terms of scientific publications has under-
gone and is still undergoing enormous growth rates. The numbers of SCI-publications 
quadrupled in the period between 2001 and 2009. Life science publications grew 
above the Chinese average in the last decade. Figure 1 depicts the absolute num-
bers of scientific papers covered by the Science Citation Index. The largest fields are – 6  Indicators 
similar to the profile in other countries – medicine, biology and biotechnology, whereas 
Traditional Chinese Medicine, food and nutrition, or medical engineering are rather 
small fields in terms of scientific publications. Organic chemistry is the slowest growing 
area among the fields analyzed. _Here, the numbers "only" tripled between 2002 and 
2009. 
Figure 1:  Absolute number of Chinese SCI publications in life science subfields, 
1995-2009 
 
Source: STN – SCISEARCH; Fraunhofer ISI calculations. 
The fastest growing fields were food and nutrition as well as Traditional Chinese Medi-
cine. However, China overall reaches a level of 11.3% of worldwide publications in 
2009, and only organic chemistry (13.9%) and TCM (12.7%) have higher than av-
erage shares. It is interesting to note that the share of Chinese authors is lowest in 
medicine (4.9%) and also rather low in medical engineering and food and nutrition. In 
consequence, the specialization profile – this indicator benchmarks the national activi-
ties against the world-wide profile – of SCI publications in the life sciences does not 
reveal many comparative advantages. Only organic chemistry and TCM are  higher 
than the world-wide average. In terms of international relevant research output, 
Chinese strengths do not include medicine, medical engineering, food and nutri-
tion. This research profile is in almost complete contradiction to the profiles of the in-
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na in the area of medicine, combined with the fact that this field is the largest one con-
sidered here, is one of the most striking findings of this analysis. If the international 
alignment – this is an index of internationalization – is used, this finding becomes even 
more prominent. All the life science fields have negative values. This means that Chi-
nese authors are not very well represented in internationally prominent journals. Con-
cerning scientific regard – this is a relative citation rate that can be seen as an indica-
tion of quality – the overall Chinese performance is now slightly above the world av-
erage, but in life sciences only organic chemistry manages a positive value. Medi-
cal engineering, pharmacy, and biotechnology are close to the average and the large 
fields of medicine, biology, as well as food and nutrition are below the world-wide aver-
age. This means that the relatively lower number of Chinese scientific publica-
tions in medicine or biology is not really targeting an international audience, and 
at the same time, is of rather low quality. In sum, China does not feature among the 
best performers in life sciences research. Although positive trends are also visible in 
these areas, the life sciences in general are not fields, in which Chinese authors show 
the most outstanding achievements. 
Table 5:  Share of Chinese SCI publications in life science subfields in world-wide 
publications, 1995-2009 
  1995  2000  2005  2009 
Medical engineering  0.7%  1.3%  2.9%  6.0% 
Organic chemistry  1.8%  4.6%  9.4%  13.9% 
Pharmacy  1.3%  2.4%  5.6%  9.8% 
Biotechnology  1.0%  2.2%  5.4%  10.7% 
Food, nutrition  0.7%  1.0%  2.7%  6.7% 
Medicine  0.7%  1.2%  2.3%  4.9% 
Biology  1.0%  2.0%  4.9%  9.1% 
TCM  2.3%  2.3%  6.8%  12.7% 
Total  2.1%  3.9%  7.7%  11.3% 
Source: STN – SCISEARCH; Fraunhofer ISI calculations. 8  Indicators 
Figure 2:  Specialization profile of SCI publications in life science subfields of four 
selected countries, 2007-2009 
 
Source: STN – SCISEARCH; Fraunhofer ISI calculations. 
Figure 3:  International alignment and scientific regard of Chinese SCI publications 
in life science subfields, 2006* 
 
* Note: A 3-years citation window is applied. The latest available publication year is therefore 2006. 
Source: Schmoch, Schulze (2010); Fraunhofer ISI calculations. 
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To assess not only the quantity but also the quality of Chinese publications in the life 
sciences, the impact factor of the SCI was used to analyze the number of publications 
in the top 20 scientific journals. As can be seen in Table 6, the share of Chinese ar-
ticles in the top journals is quite low. Except for organic chemistry and food and nutri-
tion, Chinese authors are hardly able to get published in the best journals in the seven 
subfields of the  life sciences analyzed  here.  The top ten publishing institutions are 
listed in more detail in Tables 7a-7g. 
Table 6:  Number and share of Chinese articles in the top 20 journals in the life 
sciences 
  Articles with 
Chinese author(s) 
Total N of articles  % of Chinese  
articles 
Medical engineering  616  17206  3.6% 
Organic Chemistry  3542  29929  11.8% 
Pharmacy  340  9277  3.7% 
Biotechnology  210  12213  1.7% 
Food and Nutrition  1322  18711  7.1% 
Medicine  314  21280  1.5% 
Biology  145  5307  2.7% 
Source: Elsevier – Scopus; Fraunhofer ISI calculations. 
Table 7a:  Top institutions publishing in the top 20 journals: medical engineering 
The University of Hong Kong   36 
Peking University   36 
Fudan University   32 
Ministry of Education China   28 
Sun Yat-Sen University   27 
Chinese Academy of Sciences   26 
Beijing Normal University   26 
Prince of Wales Hospital Hong Kong   26 
Zhejiang University   24 
Source: Elsevier – Scopus; Fraunhofer ISI calculations. 10  Indicators 
 
Table 7b:  Top institutions publishing in the top 20 journals: organic chemistry 
Shanghai Institute of Organic Chemistry Chinese Academy of Sciences   547 
Zhejiang University   226 
State Key Laboratory of Applied Organic Chemistry   156 
Nankai University   152 
Beijing National Laboratory for Molecular Sciences   147 
Peking University   141 
Fudan University   140 
Chinese Academy of Sciences   133 
Graduate University of Chinese Academy of Sciences   101 
Wuhan University   95 
Source: Elsevier – Scopus; Fraunhofer ISI calculations. 
Table 7c:  Top institutions publishing in the top 20 journals: pharmacy 
Shanghai Jiaotong University   26 
Peking University   21 
Shanghai Institute for Biological Sciences Chinese Academy of Sciences   20 
Fudan University   19 
Shandong University   18 
The University of Hong Kong   17 
Shanghai Institute of Materia Medica, Chinese Academy of Sciences   15 
China Pharmaceutical University   13 
Chinese Academy of Medical Sciences   13 
Shenyang Pharmaceutical University   12 
Source: Elsevier – Scopus; Fraunhofer ISI calculations. 
Table 7d:  Top institutions publishing in the top 20 journals: biotechnology 
The University of Hong Kong   18 
Peking University   16 
National Institute of Biological Sciences, Beijing   11 
Shanghai Institute for Biological Sciences Chinese Academy of Sciences   9 
Ministry of Education China   8 
Chinese University of Hong Kong   8 
Chinese Academy of Sciences   8 
Shanghai Jiaotong University   8 
Tsinghua University   8 
Source: Elsevier – Scopus; Fraunhofer ISI calculations. Indicators  11 
 
Table 7e:  Top institutions publishing in the top 20 journals: food and nutrition 
China Agricultural University   120 
Zhejiang University   115 
Chinese Academy of Sciences   76 
Jiangnan University   74 
Nanjing Agricultural University   60 
The University of Hong Kong   58 
Chinese Academy of Agricultural Sciences   51 
South China University of Technology   45 
Chinese University of Hong Kong   44 
Southern Yangtze University   42 
Source: Elsevier – Scopus; Fraunhofer ISI calculations. 
Table 7f:  Top institutions publishing in the top 20 journals: medicine 
Chinese University of Hong Kong   30 
The University of Hong Kong   28 
Peking University   20 
Prince of Wales Hospital Hong Kong   15 
The Fourth Military Medical University   15 
Chinese Center for Disease Control and Prevention   14 
Xijing Hospital   11 
Shanghai Jiaotong University   9 
Fuwai Hospital   9 
Ministry of Health of People's Republic of China   9 
Source: Elsevier – Scopus; Fraunhofer ISI calculations. 
Table 7g:  Top institutions publishing in the top 20 journals: biology 
National Institute of Biological Sciences, Beijing   20 
Institute of Genetics and Developmental Biology Chinese Academy of 
Sciences  
19 
Peking University   16 
China Agricultural University   12 
Yale University   9 
Institute of Botany Chinese Academy of Sciences   9 
Chinese Academy of Agricultural Sciences   9 
The University of Hong Kong   8 
Institute of Plant Physiology and Ecology, Shanghai Institute for Biological 
Sciences CAS 
8 
Tsinghua University   7 
Source: Elsevier – Scopus; Fraunhofer ISI calculations. 12  Indicators 
 
3.3  Patents 
Patent applications are one output measure of R&D activities, especially of companies. 
On the one hand, these are a good and reliable indicator due to their procedural re-
quirements. On the other hand, patents are much more application-oriented than for 
example scientific publications, as they provide information about technical solutions 
for very specific problems. The life sciences patents have been discussed for a long 
time and recently especially gene patents as well as patent protection for certain phar-
maceuticals (e.g. AIDS treatment medicine) have been challenged by the public. Life 
sciences are the only area in which the system of patent protection is being contested 
in this way. 
Table 6 shows the absolute number of Chinese patent applications to the State Intel-
lectual Property Office (SIPO) of China between 1996 and 2007, which is currently the 
most recent year available for patent analyses.5
                                                 
5  As patents are used here as an output of R&D processes, the date of world-wide first pa-
tent filing – the so called priority date, which is the earliest recorded date in the patent sys-
tem – is the most appropriate as this comes closest to the date of invention. Patents are 
published with a delay of 18 months after application, so 2007 is the latest completely 
available priority year in 2010. The 2007 priority filings were published in the years 2008 
and 2009 (18 month delay). Only the respective patent office – in this case SIPO – is able 
to publish statistics on the more recent priority years without the 18 months delay. Howev-
er, they only publish rather general statistics so that analytical depth is not possible, e.g. in 
the subfields of the life sciences. 
 Again, the absolute numbers of Chi-
nese patent applications have grown very rapidly and this growth has even accele-
rated recently. In parallel to the overall growth at the SIPO, the shares of Chinese in-
ventors in relation to the total applications to the office (including also foreigners' filings 
in China) have also grown. In other words, Chinese inventors were mainly respon-
sible for the overall growth in patent applications at the SIPO. In 2007 63.5% of 
patents filed in China had Chinese inventors (and in consequence 36.5% were foreign-
ers). It is interesting to note that, in genetics, in TCM, as well as in biotechnology 
and pharmaceuticals, the shares of Chinese inventors in China are far above this 
average. Medical instruments as well as organic basic materials do not show above-
average activities by Chinese inventors. The share of electronic medical instruments is 
extremely low (42.5%) and the absolute number of 767 filings in relation to the total of 
almost 116.000 is also low. Indicators  13 
 
Table 8:  SIPO (invention patents) and transnational* patent applications of Chinese 
inventors in the field of life sciences, 1996-2007 
  1996  2000  2004  2007  % of total 
in 2007 
  SIPO applications 
Biotechnology and agents  748  4,862  5,889  9,918  78.5% 
Pharmaceuticals  1,034  4,950  6,891  10,211  77.8% 
Genetics  156  1,159  1,574  1,571  95.9% 
Organic basic materials  177  1,993  1,277  2,195  62.2% 
Electronic medical instruments  72  148  426  767  42.5% 
Medical instruments  212  356  803  1,485  51.4% 
TCM core  502  889  7,160  7,157  71.7% 
TCM general  240  971  3,763  3,742  95.2% 
Total  10,135  22,897  63,775  115,882  63.5% 
  Transnational applications 
  1996  2000  2004  2007  % of total 
in 2007 
Biotechnology and agents  27  1,006  262  507  2.7% 
Pharmaceuticals  26  1,005  256  492  2.9% 
Genetics  11  699  59  93  3.1% 
Organic basic materials  7  38  76  224  3.6% 
Electronic medical instruments  1  7  20  94  2.3% 
Medical instruments  4  28  71  125  1.5% 
TCM core  12  33  40  85  5.5% 
TCM general  18  602  146  313  3.3% 
Total  229  1,821  3,037  7,619  3.6% 
Note: TCM core covers medicinal preparations and selected foodstuffs with ingredients from 
animals or plants. TCM general covers medicinal preparations with organic ingredients in gen-
eral. * Transnational patents are families with at least a PCT and an EPO application (see 
(Frietsch, Schmoch 2010). 
Source: EPA – PATSTAT; Fraunhofer ISI calculations. 
What has been said so far only holds for the SIPO, which of course only covers the 
Chinese market for technologies. To assess the international competitiveness of life 
science technologies made in China, an international market perspective is necessary. 
This is taken by examining the transnational patent applications (Frietsch, Schmoch 
2010), which are patent families that have at least one member filed at the European 
Patent Office or via the Patent Cooperation Treaty administered by WIPO (World Intel-
lectual Property Office). Whereas the absolute numbers here grew very quickly, the 
performance of Chinese life sciences is still rather restricted on an international 
level. While Chinese inventors hold a share of 3.6% in total transnational applications, 14  Indicators 
 
the Chinese shares are below this level in all the life sciences fields, except for Tradi-
tional Chinese Medicine and organic basic materials. It is worth mentioning that the 
numbers for the year 2000 are biased due to a single company called BioWindow, 
which filed more than 1000 patents in the years 1999 and 2000 on an international lev-
el, none of which, however, passed the early examination phase. This company’s ap-
plications were mainly in the areas of biotechnology, pharmaceuticals, and genetics.6 
BioWindow filed patents that were very similar to other applications and to other com-
panies’ findings so that prior art existed and the novelty7
Figure 4:  Specialization profile of SIPO patent applications, 2005-2007 
 criteria, which any patent has 
to fulfill on the international level, was violated. This company was "inspired" by the 
human genome project (Frietsch, Wang 2007). 
 
Note: TCM core covers medicinal preparations and selected foodstuffs with ingredients from 
animals or plants. TCM general covers medicinal preparations with organic ingredients in general. 
Source: EPA – PATSTAT; Fraunhofer ISI calculations. 
                                                 
6  These fields are not completely distinct in terms of the underlying patent classification so 
that some double counting has to be accepted 
7  On an international level the novelty criteria means world-wide novelty. Until the recent 
reform of the Chinese patent law, the novelty criteria at SIPO effectively only covered ap-
plications filed in China, so only Chinese prior art was taken into account. Furthermore, 
public use and public knowledge of certain technologies in China and not world-wide were 
taken as prior art. In 2009 the world-wide standard of examination of prior art was also in-
troduced in China, but it remains to be seen whether it will be effectively applied in the 
same way. 
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The patent applications filed at SIPO are depicted in Figure 4. Chinese inventors are 
relatively strong in biotechnology, pharmaceuticals, genetics, and TCM , while 
they are comparatively weak on a national level in organic basic materials and 
especially medical instruments. Again, as was the case with scientific publications, 
this profile is very different to what the three large industrialized countries Germany, the 
USA, and Japan are doing in China. Germany and the USA are especially active in 
medical instruments and organic basic materials, while Japanese inventors do not en-
gage in the life sciences in China, apart from some activities in genetics and Traditional 
Chinese Medicine (or its Japanese equivalent). 
The technological competitiveness on a transnational level is shown in Figure 5, which 
clearly shows that the United States is the dominating country in the life sciences on a 
world-wide scale. At the same time, it also becomes evident that China is not able to 
prove any comparative advantage in the life sciences on a transnational level. 
Only Traditional Chinese Medicine (or its equivalent like homeopathic or alternative 
medicine) stands out on the plus side for China. The biggest deficiencies are visible 
once again in the area of medical instruments. 
Figure 5:  Specialization profile of transnational* patent applications of selected 
countries, 2005-2007 
 
Note: TCM core covers medicinal preparations and selected foodstuffs with ingredients from 
animals or plants. TCM general covers medicinal preparations with organic ingredients in gen-
eral. * Transnational patents are families with at least a PCT and an EPO application (see 
(Frietsch, Schmoch 2010). 
Source: EPA – PATSTAT; Fraunhofer ISI calculations. 
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3.4  Foreign Trade 
At the end of the day, the markets for goods and commodities are where all the re-
search and development as well as patenting activities have to take effect, in one way 
or the other. As the largest exporting country in the world, China has to transfer in-
vestments in science and technology to international markets for high-tech goods. It is 
these international markets, where the Chinese have to prove their abilities and capa-
bilities on a competitive basis. Based on this, strengths and weaknesses in science and 
technology applications can be assessed in a comparative way. 
Table 9:  China's shares of world trade and export-import balance in life sciences, 
1995-2008 
  1995  2000  2005  2008 
  High-tech 
Biotechnology and agents  6.3%  1.7%  1.0%  0.8% 
Pharmaceuticals  0.3%  -0.9%  -0.6%  -0.5% 
Organic basic materials  -14.4%  -11.6%  -9.1%  -3.0% 
Electronic medical instruments  -2.8%  -1.3%  -0.5%  -0.1% 
Medical instruments  0.0%  0.3%  0.3%  0.4% 
  All life sciences 
Sap, pectin, mucilage, algae, herbal substances  1.0%  0.2%  0.1%  0.1% 
Organic chemical products  -12.7%  -11.4%  -8.8%  -2.6% 
Medicine and pharmaceuticals  8.8%  1.3%  0.6%  0.4% 
Essential oil, scents, polish, soaps  -2.9%  -0.9%  -0.2%  -0.1% 
Medical instruments  0.1%  0.3%  0.3%  0.3% 
Source: UN – COMTRADE; Fraunhofer ISI calculations. 
China's export profile is characterized by enormous differences ranging between lead-
ing-edge technologies, which require high investment in R&D, and low-tech areas, 
where price competition is more relevant than technology or quality competition. At 
present, China is solely responsible for more than 16% of the world-wide exports 
of processed goods. However, the finding from the analysis of scientific publications 
as well as patents, namely that the life sciences are not a Chinese strength, also 
holds for international trade. If all the life sciences-related goods are taken into ac-
count, China has the largest shares in sap, pectine, algae and the likebut only accounts 
for 2.3% of the global trade in medicine and pharmaceuticals, a figure which is even 
decreasing over time. When looking at the high-tech areas only, the situation is even 
clearer:  the world-wide production of pharmaceuticals does not take place in 
China and the Chinese world market shares have actually fallen since the mid Indicators  17 
 
1990s. Even if it is taken into account that the Chinese exports are dominated by ICT-
related goods and that these technologies are responsible for the overall huge share of 
China in world-wide trade, the market shares of 5.5% in biotechnology, 7.6% in organic 
basic materials and 5-6% in medical instruments are still far below what would be ex-
pected from a technology-oriented country of the size of China. 
The export-import-balance provides indications for the Chinese supply and demand of 
life sciences goods on world markets. The lower panel of Figure 7 illustrates data in 
relation to the overall Chinese trade surplus of processed goods. In 2008 an almost 
balanced pattern results, while until recently especially organic basic materials but also 
medical instruments had a trade deficit. Biotechnology and agents as well as medicine 
and pharmaceuticals were exported more than imported between the mid 1990s and 
the mid 2000s, but their contribution to the trade surplus has diminished over time. 
This, however, is a direct effect of the increasing Chinese demand for biotechnolo-
gy and pharmaceuticals that has not been accompanied by a similar increase of 
the Chinese supply in international markets. 
In consequence, the export specialization profile of China does not show any 
positive values in the life sciences, either in high-tech or in total life sciences ex-
ports. Figure 6 again provides evidence for the strong position of the US in the life 
sciences and also for some comparative advantages for Germany in these fields. 
Figure 6:  Export specialization profile of selected countries, 2006-2008 
 
Source: UN – COMTRADE; Fraunhofer ISI calculations. 
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Figure 7:  China's export-import specialization profile (revealed comparative advan-
tage (RCA)), 2006-2008 
 
Source: UN – COMTRADE; Fraunhofer ISI calculations. 
4  Summarizing conclusions 
The life sciences – that is medicine, biology, biochemistry, biotechnology and several 
other adjacent areas like medical instruments or food and foodstuffs – do not currently 
feature among China’s strengths. Considerable comparative advantages for China can 
neither be detected concerning scientific publications nor in terms of patents. While 
organic chemistry and Traditional Chinese Medicine have an activity level above the 
world-wide average if scientific publications are taken into account, areas like biotech-
nology and pharmaceuticals are slightly below, while medical equipment and especially 
medicine are far below the world average. Increases in the relative position can be de-
tected in almost all areas, but the largest field of medicine shows a rather smooth 
change. This finding is also supported by a recent study on China's scientific output 
(Adams et al. 2009). Biology is among the fastest growing areas, but the shares in 
worldwide publications in all life science fields still remain far below the Chinese aver-
age. 
Genetics and Traditional Chinese Medicine feature prominently in the patent applica-
tions of Chinese inventors to the State Intellectual Property Office (SIPO) of China, 
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while medical equipment and organic chemistry are not among their strengths. The 
Chinese profile is completely different on  the  international technology markets. Al-
though some strengths in genetics and in Traditional Chinese Medicine are still visible, 
it becomes even more evident that no comparative advantages exist in medical equip-
ment, even though this area has been among the most dynamic ones in recent years. 
The patent activities in biotechnology and pharmaceuticals are not able to meet inter-
national  expectations, but those in organic chemistry almost reach the international 
average unlike the national context. These findings suggest two effects: On the one 
hand, it seems that foreign activities in China are focused on certain areas (medical 
instruments and chemistry). This is why it  is much harder for Chinese inventors to 
reach a relatively good position in the Chinese technology market. On the other hand, 
these results corroborate once again that the national activities are not yet internation-
ally competitive in all areas and  that, so far, there are no  comparative advantages 
compared to the established industrialized and innovation-oriented countries. 
Trade deficits exist in organic basic materials, in pharmaceuticals and in parts of medi-
cal equipment, which means that China imports more of these goods than it exports. If 
biotechnology products are considered, the  picture  changes  and China achieves  a 
trade surplus, albeit with a decreasing trend, as the national demand is growing even 
faster than the supply to international markets. Furthermore, China does not occupy an 
above-average position in the world markets in any of the life sciences or adjacent 
areas. China's share in world-wide exports of processed goods was 15.7% in the pe-
riod 2006 to 2008. This share is dominated by information and communication technol-
ogies. Its share in the world trade of pharmaceuticals was only 0.7% with a decreasing 
tendency  and the other goods like biotechnology, organic chemistry or medical instru-
ments are also clearly below the Chinese average with values between 4 and 6%. 
It has to be emphasized that the Chinese government and Chinese companies have 
been able to greatly increase the expenditures on R&D in recent years, also in the 
fields of the life sciences. Between 2000 and 2007 total expenditure more than qua-
drupled which may also correspond to a similar increase in the life sciences. A recent 
study on the Chinese biotechnology market names China as the fastest growing mar-
ket in the world and bases this conclusion on a survey of almost 4,500 small and me-
dium-sized companies supposed to have an increasing number of drugs in the pre-
clinical or even clinical phase, with a considerable number even in the pre-registration 
phase (Raabe, Leewe 2010). However, another recent study (Bührlen, Vollmar 2009) 
surveying biomedical innovation and clinical research does not list China among the 
top countries. Although they show the highest growth rate, the number of clinical tests  
is on the same absolute level as much smaller countries like Denmark, Austria or South 
Korea. 20  Summarizing conclusions 
 
Despite that fact that our empirical data did not reveal any strong positive trends, it is 
important to acknowledge the increased efforts on the input side. The National Science 
Foundation of China (NSFC) has more than tripled its number of life sciences projects 
and it still spends more than one third of its funding on projects in this area. A small 
number (about 2-3%) of NSFC projects deals with Traditional Chinese Medicine. This 
is an area of great hope for China in an international market perspective as well. But 
these high hopes cannot yet be backed up  by empirical data,  even  though China 
shows some strengths in terms of publications and patent filings. It has to be stressed 
that other countries also conduct similar research and have been able to transfer their 
research into patents and products – although they call this homoeopathic or alterna-
tive medicine rather than Traditional Chinese Medicine. 
While the Chinese innovation system in general is characterized by enormous growth 
rates on the input side and some respectable successes on the output side, this is not 
yet true for the life sciences. The major challenge for China is the transfer of research, 
development, and patents to industry and markets. In terms of the life sciences, the 
challenges here are even larger as there is not only an enormous gap to overcome. 
Because the life sciences are a field in which traditional, industrialized countries are 
actively engaged, they are continuing to build on their currently very strong relative 
position, so that closing this gap will be even harder to do. Annex  21 
 
A.1  Annex: Case Studies of TCM Companies in China 
A.1.1  Tong Ren Tang (TRT) 
Beijing TRT has a history reaching back over 340 years and is a well-known brand in 
the traditional Chinese medicine industry.8
Beijing TRT Hospital of TCM combines medicine and medical treatment featuring the 
TRT brand and TRT traditional Chinese culture. The hospital not only provides Chinese 
traditional medicine (supplemented by western medicine), but has also established a 
service system including an expert outpatient service, general outpatient service, in-
spection centre and wards. 
 Under the overall framework of the TRT 
Group, three businesses have been established, namely, modern pharmacy, a retail 
business, and medical services. The group currently has 2 listed companies (on the 
Shanghai Stock Exchange and the Hong Kong Stock Exchange GEM), and more than 
800 retail stores at home plus 36 joint venture stores in another 15 countries and re-
gions. In addition, some new products have entered a mature market stage. 
Since 2000, TRT has established 13 traditional medicinal plantations according to the 
Medicinal Collection and Planting Regulations (GCAP) standards (7 of them have 
passed GCAP certification) involving a total investment of 58 million RMB. TRT has 
recently been paying more attention to research and innovation. The Beijing TRT Re-
search Institute was established with funding from the TRT Group, the Chinese Acad-
emy of Chinese Medical Sciences, and two pharmaceutical companies, and has em-
barked on research and development in natural medicine, bio-medicine, food and 
healthcare products, as well as cosmetics. 
By the end of 2009, TRT had maintained a 2-digit growth rate in thirteen consecutive 
years. The sales for 2009 exceeded 10 billion RMB and the profits 0.8 billion RMB, 
increasing 12% and 16% since 2008, respectively. TRT earned $25.4 million in exports 
in 2009, an increase of 10.3% since 2008, and is ranked No.1 in the TCM industry in 
China. At present, TRT holds total assets worth 10.2 billion RMB and has about 14,000 
employees. 
A.1.2  Tasly 
Tasly, founded in 1994, is a younger entrant to the TCM industry. By sticking to the 
pharmaceutical industry, aiming at a broad healthcare industry, and adopting scientific 
research and innovation, Tasly has become a hi-tech group whose business encom-
                                                 
8  http://www.tongrentang.com/en/abouttrt/profile.php. Retrieved on March 3, 2010. 22  Annex 
 
passes modern TCM, chemical medicine, biological medicine, healthcare products, and 
functional food. 
The main products and markets for Tasly are anti-virus medicine, anti-flu medicine, 
cardiovascular medicine, cerebrovascular medicine, anti-tumor medicine, immune sys-
tem medicine, and digestive system medicine. 
Tasly has built up three production bases. The first is dedicated to the production of 
modern TCM and is based in Tianjin. The second is located in Shanghai and focuses 
on biomedicine production, whereas the production base in Jiangsu targets chemical 
medicine – traditional Western and Chinese medicine. Finally, a herbal plantation is 
located in Shanxi. There are 6 regional subsidiaries and 191 local offices in China un-
der the framework of the Group. Moreover, the Tasly Group has set up two systems for 
the international market, international trade and international direct sales, covering 20 
countries and areas from developing to developed countries. 
Tasly has continuously invested in and promoted their scientific and innovative activi-
ties. It has established a national technology centre for enterprises and a national post-
doctoral scientific research institution. 
Tasly always emphasizes the protection of intellectual property rights. By the end of 
2006, Tasly had applied for 694 intellectual property rights, among which are 599 pa-
tents of invention, and 22 international PCT patents. Its major products have been reg-
istered in 34 countries and regions. Tasly has ambitious and clear plans for internatio-
nalization. 
In the period between January and November in 2009, the sales of the Tasly Group 
reached 6.93 billion RMB and the profits were 0.84 billion RMB, an increase of 16% 
and 46%, respectively, compared to the same period in 2008. By the end of 2007, the 
total assets of the Group reached 8.5 billion RMB, and the revenue in sales from the 
overseas market exceeded $80 billion. Note that its sales in Africa have doubled an-
nually for three consecutive years. Based on its quick growth in the international mar-
ket, Tasly has set itself a new goal of making 50% the annual growth rate in sales and 
profits. References  23 
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